Drug Trial Radar · NCT04411654
Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
7
Actual
Start
Jun 29, 2021
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- Prevail TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Jun 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 months, up to 24 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
J3Z-MC-OJAB is an open-label, Phase 1/2, multicenter study to evaluate the safety and efficacy of single-dose LY3884961 (formerly PR001) in infants diagnosed with Type 2 Gaucher disease (GD2). For each patient, the study will be approximately 5 years in duration. During the first 12 months after dosing, patients will be evaluated for the effects of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will be followed up for an additional 4 years to monitor safety and changes on selected biomarkers and clinical outcomes.
Conditions
- Gaucher Disease, Type 2
Interventions
LY3884961Genetic
Participants will receive a single dose of LY3884961 administered intracisternally.
MethylprednisoloneDrug
Single IV pulse administered as concomitant medication.
SirolimusDrug
Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.
PrednisoneDrug
Administered orally as concomitant medication, followed by dose tapering.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events leading to discontinuationTime frame: Year 5
- Immunogenicity of AAV9 and GCase in bloodTime frame: Up to Year 2
- Immunogenicity of AAV9 and GCase in CSFTime frame: Up to Year 1
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital, 747 52nd St
Oakland, California
University of Minnesota Masonic Children's Hospital, 2450 Riverside Avenue
Minneapolis, Minnesota
NYU Medical Center, 305 Second Ave, Suite 16
New York, New York
Children's Hospital of Pittsburgh, 4401 Penn Avenue
Pittsburgh, Pennsylvania
Lysosomal & Rare Disorders Research and Treatment Center
Fairfax, Virginia
Manchester Centre for Genomic Medicine, 6th Floor, St Mary's Hospital, Oxford Road
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.